Reducing Vertical Transmission of Hepatitis B in Africa
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
Hepatitis B virus is an infection that can be easily transmitted from women to newborns at
the time of delivery. Our objective is to identify novel options that are effective and safe
in preventing perinatal transmission of hepatitis B in Africa. The REVERT-B study (Reducing
Vertical Transmission of Hepatitis B in Africa) is a clinical trial designed to test a new
strategy of using antiviral medication in high-risk pregnant women and newborns to reduce the
risk of hepatitis B transmission. The study will measure efficacy, safety, tolerability and
adherence to medication.
Phase:
Phase 3
Details
Lead Sponsor:
University of Alabama at Birmingham
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) NIH-NICHD